Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin.
The aim of this study was to evaluate the effect of antihypertensive treatment with doxazosin on left ventricular anatomy and function. Therefore, after 4 weeks of washout with placebo (phase 1), doxazosin (dosage range from 1 to 16 mg, plus hydrochlorothiazide when necessary) was given to 11 essential hypertensive patients (6 M, 5 F, age range 34-63 years) for 8 weeks (phase 2) in order to achieve diastolic blood pressure values less than 90 mmHg; this dosage was then maintained for a further 20 weeks up to the end of the study (phase 3). Blood pressure was significantly reduced (Anova P less than 0.05), while heart rate did not change. A significant reduction of left ventricular mass index (from 128.5 +/- 26 to 114 +/- 23 g/m2, at the end of phase 1 and 3 respectively, P less than .001)) was observed. Before and during treatment left ventricular systolic function, both at rest and during stress (handgrip and cold pressor tests), evaluated by fractional shortening as related to end-systolic stress, in every case within 95% confidence limits, was calculated in normal subjects. Diastolic function, as evaluated by the ratio between peak early and atrial velocities of transmitral flow examined by pulsed doppler was significantly improved. Plasma catecholamine concentrations, plasma renin activity and plasma aldosterone did not change. A significant reduction of plasma cholesterol concentration was observed. These results confirm that doxazosin is a well tolerated and effective antihypertensive drug, with a favourable effect on blood lipids and they indicate that its longterm administration can induce a significant reduction of left ventricular mass.
Department of Medical Sciences, University of Brescia, Italy.
E
E
Agabiti-Rosei
M L
ML
Muiesan
D
D
Rizzoni
R
R
Zulli
S
S
Calebich
M
M
Beschi
M
M
Castellano
G
G
Muiesan
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000450:Aldosterone / Q000097:blood; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D006332:Cardiomegaly / Q000188:drug therapy* / Q000209:etiology; D002395:Catecholamines / Q000097:blood; D003971:Diastole / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D017292:Doxazosin; D004359:Drug Therapy, Combination; D005260:Female; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006352:Heart Ventricles / Q000473:pathology; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D011224:Prazosin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012083:Renin / Q000097:blood; D012146:Rest / Q000502:physiology; D013312:Stress, Physiological / Q000503:physiopathology; D013599:Systole / Q000502:physiology; D013997:Time Factors
D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D002395:Catecholamines; D008055:Lipids; D006852:Hydrochlorothiazide; D000450:Aldosterone; D012083:Renin; D017292:Doxazosin; D011224:Prazosin